Workday Posts Upbeat Q2 Results; Insider Confidence Boosts YS Biopharma
- August 25th, 2023
- 435 views
Workday, Inc. (Nasdaq: WDAY), a prominent enterprise software company, reported second-quarter fiscal 2024 earnings of $1.43 per share, surpassing the consensus EPS estimate of $1.26. The company's quarterly sales reached $1.79 billion, slightly exceeding analysts' projected revenue of $1.77 billion.
Additionally, Workday has revised its fiscal 2024 subscription revenue outlook to a range of $6.570 billion to $6.590 billion, marking an 18% year-over-year growth. Moreover, the company has increased its fiscal 2024 non-GAAP operating margin guidance to 23.5%.
$WDAY was trading at $231.79 in after-hours on Thursday, up $6.92 (+3.08%).
In other news, YS Biopharma Co., Ltd. (Nasdaq: YS) said that its Founder and Chairperson, Mr. Yi Zhang, and its Director and CEO, Dr. Hui Shao have purchased 429,188 and 46,300 of its ordinary shares respectively on the open market. Zhang's shares were acquired at an average price of $1.407, while Shao's shares were purchased at an average price of $1.46.
In pre-market, $YS was trading at $1.17, showing an increase of $0.41 (+54.96%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login